AAD 2017 Updates!

Paul M. Graham, D.O.

The 2017 American Academy of Dermatology Conference in Orlando Florida has officially concluded. With tens of thousands in attendance and over a thousand presentations occurring over five days, this conference was nothing more than a success and a vital resource for medical providers across the country. Whether in attendance for the education, the networking, or for that next big business deal, there was something to be had for everyone. The diversity and innovation of this year’s conference demonstrates the strength and commitment of the American Academy of Dermatology within our specialty.

Conference Highlights

1. The introduction  of Crisaborole, a new topical nonsteroidal anti-inflammatory medication for those individuals that suffer from atopic dermatitis or eczema
   • Studies demonstrated favorable effectiveness and safety in patients as young as 2 years old
2. Acne in adult women may be associated with an underlying hormonal disorder
   • Local treatment of acne in women should only be initiated after intensive hormonal investigation and examination of the reproductive system
3. Studies demonstrate that total body skin examinations are highly sensitive for the detection of skin cancer when performed by trained dermatologist
   • Skin cancers were smaller and less advanced when detected on full body skin examinations
   • Dermatologist demonstrate significant superiority in detecting basal cell skin cancer
   • Patients and primary care physicians detected squamous cell skin cancer less than 60% of the time demonstrating a high rate of non-detection
4. Skin infections among US high school athletes is highest in wrestlers, accounting for 73.6% of those affected
   • The most common infection was bacterial (60.6%), followed by fungal (27.2%) and herpetic (4.8%)
   • The head and face were the most common site of infection
5. A new treatment for persistent facial redness was introduced!
   • Patients treated with oxymetazoline cream 1% reported very high levels of satisfaction in the resolution of facial redness with long lasting redness reduction up to 12 hours
6. The use of oral tranexamic acid in the treatment of melasma (facial pigmentation) demonstrates reduction in pigment appearance
   • Patients were treated with 250mg of tranexamic acid twice daily for 3 months, demonstrating a 59% improvement in appearance

Next year, the AAD Conference will be held in San Diego, California from February 16th-20th.

Please note, our medical disclaimer applies to all information, images, recommendations, and comments published on this page.